

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021

<https://marketpublishers.com/r/B7B0A831987CEN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: B7B0A831987CEN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Understanding

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is regarded as an orphan tumour due to its rareness and usual clinical aggressiveness with poor response to conventional chemotherapies. It derives from precursors of plasmacytoid dendritic cells (pDCs), also known as professional type I interferon-producing cells or plasmacytoid monocytes. In the Revised WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, BPDCN is quoted after acute myeloid leukaemia. This reflects the fact that the gene signature of the cell of origin is much closer to myeloid than lymphoid

precursors. It has a dismal prognosis, with most patients dying within one year when treated by conventional chemotherapies. The diagnosis is challenging, since neoplastic cells can resemble lymphoblasts or small immunoblasts, and require the use of a large panel of antibodies, including those against CD4, CD56, CD123, CD303, TCL1, and TCF4. The morphologic and in part phenotypic ambiguity explains the uncertainties as to the histogenesis of the neoplasm that led to the use of various denominations.

“Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline landscape is provided which includes the disease overview and Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy treatment guidelines. The assessment part of the report embraces, in depth Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy R&D. The therapies under development are focused on novel approaches to treat/improve Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Emerging Drugs Chapters

This segment of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Emerging Drugs

IMGN 632: ImmunoGen

IMGN632 is a CD123-targeting ADC in clinical development for hematological malignancies, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and acute lymphocytic leukemia (ALL). IMGN632 uses one of ImmunoGen's (the "Company") novel indolinobenzodiazepine (IGN) payloads, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against tumor cells, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads.

The European Medicines Agency (EMA) granted orphan drug designation to IMGN632 for the treatment of BPDCN in June 2020; IMGN632 also holds this designation in the US. In October 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory BPDCN.

Further product details are provided in the report.....

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Therapeutic Assessment

This segment of the report provides insights about the different Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy

There are approx. 5+ key companies which are developing the therapies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy. The companies which have their Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drug candidates in the most advanced stage, i.e. phase I/II include, ImmunoGen

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs.

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Report Insights

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs?

How many Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AbbVie

ImmunoGen

Key Products

Venetoclax

IMGN 632

Research programme: Allogeneic gene-edited chimeric antigen receptors T-cell therapy

Contents

Introduction

Executive Summary

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy : Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - DelveInsight's

Analytical Perspective

In-depth Commercial Assessment

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy companies' collaborations, Licensing, Acquisition -Deal Value Trends

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Early Stage Products (Phase I/II)

Comparative Analysis

IMGN632: ImmunoGen

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical Stage Products

Comparative Analysis

Research programme: Allogeneic gene-edited chimeric antigen receptors T-cell therapy: Allogene Therapeutics

Product Description

Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Companies
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Products
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Unmet Needs
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Market Drivers and
Barriers
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Future
Perspectives and Conclusion
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Analyst Views
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) malignancy - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/B7B0A831987CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B7B0A831987CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970